Now, a one-two drug punch approach to KO a lethal cancerJune 8th, 2009 - 2:15 pm ICT by ANI
London, June 8 (ANI): Researchers have found that a two-drug combination of Zileuton and Gleevec could be a potent treatment of a lethal cancer, called chronic myeloid leukemia (CML).
Dr, Shaoguang Li, The Jackson Laboratory Adjunct Professor, led a team of researchers who identified a gene, called Alox5, involved with the inflammatory response that could hold the key to treating or even preventing CML.
The researchers also showed that an asthma medication for human patients was an effective treatment for CML in mice, reports Nature magazine.
Alox5 processes essential fatty acids to leukotrienes, which are important agents in the inflammatory response.
However, the researchers believe that Alox5 has a more sinister side-it is vital to the development and maintenance of cancer stem cells.
They say that cancer stem cells must be targeted for effective treatment of many cancers, but direct evidence is still lacking.
In the new study, the researchers found that CML did not develop in mice without Alox5 because of impaired function of leukemia stem cells.
Furthermore, Alox5 deficiency did not affect normal stem cell function, providing the first clear differentiation between normal and cancer stem cells.
The researchers also treated mice with CML with Zileuton- an asthma medication that inhibits the Alox5 inflammation pathway, as well imatinib-commonly known as Gleevec, the most effective current leukemia medication.
They found that imatinib effectively treated CML, but Zileuton was more effective. The two drugs combined provided an even better therapeutic effect.
The researchers are now seeking patent protection on the novel approach to treat CML that Li and colleagues have demonstrated.
The findings reveal how leukaemia stem cells are distinct from normal stem cells and how they can be targeted in cancer therapies.
The study has been published in the journal Nature Genetics. (ANI)
- 'Chewing betel leaf may help fight cancer' - Sep 18, 2012
- Drug used to treat asthma 'prevents spread of breast cancer' - Nov 04, 2010
- Key cause of chronic leukemia progression identified - Mar 05, 2010
- Drug combo helps protect hearing - Feb 24, 2011
- Fish oil may hold key to leukaemia cure - Dec 23, 2011
- Asthma drug could help fight Alzheimer's disease - Mar 26, 2011
- Why don't you reduce cancer drug price, SC asks Novartis - Sep 11, 2012
- Drug-chemo combo doubles survival in high-risk childhood leukaemia patients - Oct 07, 2009
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- New study shows evidence of stem cells' pivotal role in cancer - Dec 22, 2010
- Intestinal stem cells offer clues to colon cancer origin and relapse - Mar 18, 2011
- Broccoli may help treat breast cancer - May 06, 2010
- SC again asks Novartis to cut cancer drug price - Sep 12, 2012
- Novel way to kill treatment-resistant breast cancer stem cells - Jan 05, 2010
- Umbilical cord cells may be useful in arthritis treatment - Nov 16, 2010
Tags: adjunct professor, asthma medication, cancer therapies, chronic myeloid leukemia, cml, drug combination, essential fatty acids, gleevec, human patients, inflammatory response, jackson laboratory, journal nature genetics, leukotrienes, nature magazine, novel approach, patent protection, sinister side, stem cells, therapeutic effect, zileuton